In Vitro Diagnostic Devices Market Analysis 2026

Additional Insights in In Vitro Diagnostic Devices Market

AI-Driven Diagnostics and Predictive Analytics in In Vitro Diagnostic Devices Market

Artificial Intelligence is transforming IVD devices by enabling rapid, accurate interpretation of complex diagnostic data. AI algorithms assist in early detection of diseases like cancer or sepsis using machine-learned patterns from blood, genetic, or imaging data. For instance, PathAI’s AI-powered pathology platforms support more accurate histological diagnostics, while companies like Roche and Abbott are integrating AI into molecular diagnostic workflows for precision medicine.

CRISPR-based Diagnostics

CRISPR-Cas systems, initially known for gene editing, are now leveraged in diagnostics due to their high specificity and programmability. CRISPR diagnostics can rapidly detect nucleic acids from pathogens like SARS-CoV-2, tuberculosis, or HPV. Sherlock Biosciences' CRISPR-powered SHERLOCK test is a groundbreaking development, offering fast, low-cost, and highly sensitive point-of-care testing solutions for pandemic preparedness and personalized

Pricing Analysis

The IVD devices market displays moderate-to-high pricing variability based on test complexity, automation, and target condition. High-end molecular diagnostic tests, such as RT-PCR or NGS panels for oncology, can command premium prices. For instance, as per research, from the payer's perspective, incorporating NGS-based testing resulted in an additional diagnostic cost of approximately USD 2,036 per patient. Meanwhile, basic immunoassays or glucose meters are highly commoditized. Regional differences in pricing are significant. For instance, North America and Western Europe often have higher price points than Asia-Pacific.

(Source:https://www.sciencedirect.com/science/article/pii/S1525157822001428)

Reimbursement Scenario

Reimbursement remains a critical driver of IVD adoption, especially in the U.S., EU, and Japan. Payers are increasingly tying reimbursement to clinical utility and real-world evidence. For instance, Medicare covers many molecular tests under the Molecular Diagnostic Services (MolDX) Program.Delays or denials in coverage, however, hinder the uptake of emerging tests like liquid biopsies.

Unmet Needs and Customer Expectations Analysis

Despite advancements, unmet needs persist in early disease detection, multiplexing, and integration with electronic health records. Patients seek greater access to self-testing with actionable results. For example, limited test access in low-resource regions hampers timely diagnosis.  Approximately 47% of the global population lacks adequate access to diagnostic services, with low- and middle-income countries (LMICs) in the World Health Organization (WHO) Africa Region experiencing the most significant barriers. Emerging needs also include interoperability and cloud-based platforms for real-time diagnostic data sharing.

Investment & Funding Scenario

The IVD devices market continues to attract robust investments, especially in molecular diagnostics, AI-driven platforms, and point-of-care testing. COVID-19 pandemic dramatically accelerated investor interest in decentralized and home testing solutions. As of April 2025, IVD companies in India have secured USD 4.03 million in equity funding across 4 rounds, a substantial increase compared to the same period in 2024, when they raised only USD 582K across 3 rounds. This reflects growing investor confidence and accelerated innovation in the Indian IVD sector. 

Regulatory Framework 

The regulatory landscape is evolving with greater scrutiny and harmonization efforts. In the U.S., the FDA regulates IVDs under the 510(k), PMA, or EUA routes, depending on risk classification. The EU’s shift from IVDD to IVDR (effective May 2022) demands stricter clinical evidence and transparency. These regulations impact timelines and go-to-market strategies, especially for startups and LDT (Laboratory Developed Test) providers. Countries like China are also tightening rules to ensure quality and safety.

Ecosystem Analysis 

Raw Material Sourcing

Raw materials for IVD devices, such as specialized plastics, reagents, microfluidics, and biosensors, are sourced from global suppliers. Companies like Thermo Fisher Scientific, Evonik Industries, MilliporeSigma (Merck KGaA), DuPont, and SABIC provide essential components such as assay reagents, polymers for test cartridges, and biochemical substrates critical to diagnostic kit manufacturing and reliability. 

(Source:https://www.dupont.com/liveo/specialty-medical-devices.html)

Manufacturers

IVD device manufacturers design, produce, and validate diagnostic systems ranging from immunoassay kits to molecular testing platforms. Global leaders like Roche Diagnostics, Bio-Rad Laboratories, Abbott Laboratories, and Siemens Healthineers are at the forefront, offering COVID-19, cancer, and infectious disease diagnostics, with technologies spanning PCR, ELISA, and point-of-care testing solutions for hospitals and labs worldwide.

(Source:https://www.roche.com/solutions/diagnostics)

Distributors and Logistics

Distributors ensure the efficient delivery and inventory management of IVD devices and reagents to hospitals, diagnostic labs, and clinics. Firms such as McKesson, Cardinal Health, and Henry Schein facilitate market penetration and cold chain logistics, while global logistics providers like DHL manage international transport, customs, and temperature-controlled shipping to meet regulatory compliance and time-sensitive demand. 

(Source:https://mms.mckesson.com/catalog/category?node=17161)

Trade Analysis

The global IVD devices trade ecosystem is shaped by cross-border collaborations and regulatory harmonization. Key exporters include the U.S., Germany, Switzerland, and Singapore, while major importers are China, India, and Brazil. Trade disruptions, including those caused by COVID-19 and geopolitical tensions, impacted reagent and test kit supplies. Free trade agreements and mutual recognition protocols are essential to maintain uninterrupted global IVD supply chains.

(Source:https://cepr.org/system/files/publication-files/60044-covid_19_and_trade_policy_why_turning_inward_won_t_work.pdf)

Recent Developments & Strategies

In February 2025, Tasso Inc., a leader in patient-centric, clinical-grade blood collection solutions, partnered with ARUP Laboratories, the largest nonprofit clinical and academic reference lab in the U.S., to co-develop and operationalize high-quality at-home blood testing services aimed at advancing clinical research. This collaboration is set to enhance accessibility, convenience, and compliance in decentralized trials. 
(Source:https://www.prnewswire.com/news-releases/tasso-and-arup-laboratories-announce-partnership-combined-offering-for-decentralized-clinical-research-biomarker-testing-302366053.html)

In March 2024, Everlife Holdings Pte Ltd, a prominent market access and distribution company operating across India and Southeast Asia, acquired Hausen-Bernstein Co. Ltd. Hausen is a well-established provider of IVD products in Thailand. This strategic move strengthens Everlife’s footprint in the Southeast Asian diagnostics market and enhances its capabilities in delivering advanced IVD solutions across the region. 
(Source:https://everlifeasia.com/2024/03/06/everlife-expands-ivd-footprint-in-thailand-through-investment-in-hausen-bernstein/)

Key Conferences & Events (2025)

Research & Development Analysis

In February 2024, Freenome, a biotechnology company focused on early cancer detection through blood-based testing, announced it had secured $254 million in funding from both new and existing investors. This substantial investment will support the advancement of Freenome's pipeline, including single-cancer and customized multi-cancer early detection tests, which are powered by its cutting-edge multiomics platform. 
(Source:https://www.freenome.com/newsroom/freenome-raises-254-million-in-new-funding-to-accelerate-its-platform-for-early-cancer-detection/)

In June 2025, Revvity, Inc. launched three new Mimix reference standards specifically designed for IVD applications. These standards are tailored to support the monitoring and validation of next-generation sequencing (NGS) and droplet digital PCR (ddPCR) assays used for detecting somatic mutations in genomic DNA (gDNA) from human samples, enhancing assay accuracy and reliability in clinical diagnostics.
(Source:https://news.revvity.com/press-announcements/press-releases/press-release-details/2025/Revvity-Introduces-New-IVD-Reference-Standards-for-Monitoring-Oncology-Diagnostic-Testing-Workflows/default.aspx)

Competetive Landscape of In Vitro Diagnostic Devices Market

The leading companies in the global IVD device market maintain their dominant positions due to a strategic blend of technological innovation, global reach, diversified product portfolios, and acquisitions. Key players include:

• Roche Diagnostics 
• Bio-Rad Laboratories 
• Abbott 
• Siemens Healthineers
• DiaSorin S.p.A.
• QuidelOrtho Corporation
• Agilent Technologies, Inc.

Roche Diagnostics, Abbott, and Bio-Rad Laboratories are considered the leading players in the IVD devices market due to their extensive product portfolios, global presence, and continued investment in innovation. Roche Diagnostics holds a dominant position with its broad assay range and advanced platforms like the Cobas systems for molecular diagnostics.

(Source:https://diagnostics.roche.com/global/en/article-listing/cobas-modular-analyzer-systems.html)

Abbott’s success stems from its rapid diagnostics segment, especially its i-STAT and ID NOW platforms, widely used during the COVID-19 pandemic.

Bio-Rad is renowned for its expertise in clinical diagnostics and life sciences tools, including its Droplet Digital PCR technology, which offers high sensitivity in detecting genetic mutations and infectious.

Other key players such as Siemens Healthineers, DiaSorin S.p.A., QuidelOrtho Corporation, and Agilent Technologies also contribute significantly to the IVD landscape. These companies strengthen the market through specialized offerings, Siemens with its immunoassay systems, DiaSorin’s focus on specialty diagnostics, and Agilent’s genomic tools, helping diversify technological capabilities and expand clinical applications globally.

Upcoming Players in In Vitro Diagnostic Devices Market

There are several emerging players in the IVD devices market that are gaining traction due to their focus on next-generation technologies, novel therapeutic approaches, and addressing unmet clinical needs. Key upcoming players are:

• Byonyks
• Renalyx
• MOMM Diagnostics

Abionic SA is redefining point?of?care diagnostics with its abioSCOPE platform, which uses patented nanofluidic immunoassays to deliver lab?quality results from just a 50 μL blood sample in under five minutes. Their rapid sepsis test based on Pancreatic Stone Protein (PSP) has earned both CE?IVDR certification and FDA 510(k) clearance, offering clinicians critical early detection capabilities in ICU and emergency settings.

SiPhox Inc. brings silicon photonics, a technology traditionally used in telecom, into at-home blood testing, enabling multiplexed biomarker analysis from simple capillary samples. Their mail-in kits and upcoming countertop device promise fast, scalable diagnostics for chronic disease markers with strong backing from Intel Capital. MOMM Diagnostics focuses on maternal and fetal health through its pioneering préXclude rapid test for early detection of preeclampsia, offering healthcare professionals accessible tools that support proactive prenatal care and reduce risk.

(Source:https://www.mommdiagnostics.com/)

The IVD devices market is moderately consolidated, with a few global players dominating high-value segments like molecular diagnostics and immunoassays, but significant fragmentation in niche and regional categories such as point-of-care and emerging markets.

SY

Supriya Yadav Verified Analyst

Research Analyst at Cognitive Market Research · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.

Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive  research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.

In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.

Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

Read more

LinkedIn Profile Book a free Consultation